Tag: amicus therapeutics
January 1, 2019
An Investor’s Guide to Clinical Trials
Clinical trials can be one of the more challenging US Food and Drug Administration processes to understand, but grasping the... December 20, 2018
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced... September 10, 2018
Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, announced... March 23, 2018
Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
Amicus Therapeutics (Nasdaq:FOLD) announced today that Japan’s Ministry of Health, Labour and Welfare has approved the oral small molecule pharmacological chaperone Galafold capsules... February 28, 2018
Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates
Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced... February 16, 2018
Amicus Therapeutics Prices Underwritten Offering of Common Stock
Amicus Therapeutics (Nasdaq:FOLD) announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share.... February 15, 2018